Embedded Files
The University of Minnesota has a rich tradition of excellence that has resulted in:
the world’s first open heart surgical procedure...
the discovery of the heart-lung machine...
and the creation of the transistorized pacemaker.
We are home to the world’s first mitral valve repair
We have introduced new heart failure therapies focused on novel devices and pharmacotherapies.
We are the only program in the country that has been awarded membership to the NHLBI Cardiovascular Cell Therapy Research Network
the recipient of one of three NHLBI-sponsored Product Assistance for Cellular Therapies (PACT)
one of three institutions to be awarded
the AHA-DeHaan Cardiac Myogenesis Center Grant,
the HeartRescue Consortium Grant,
and the NHLBI U01 Progenitor Cell Biology Consortium Grant.
Our cardiovascular division is the recipient of a T32 grant from the National Heart, Lung, and Blood Institute, dedicated to the development of clinician-scientists amongst our cardiology fellows.
These awards emphasize our infrastructure/expertise and our ability to translate basic science discoveries to our patients with heart disease. These awards also provide unprecedented opportunities to our fellows.
Lillehei Heart Institute
Lillehei Heart Institute
We are also home to the Lillehei Heart Institute which is a premier clinical and basic science research program focusing on cardiovascular genomics, cardiogenesis, stem cell therapies, personalized medicine, heart failure, arrhythmias, resuscitation, vascular biology, myocardial regeneration and device design for treatment of cardiovascular diseases.
The University of Minnesota has made an outstanding institutional investment in infrastructure, faculty support, faculty recruitments and core research facilities for the Lillehei Heart Institute (LHI). The LHI currently has:
more than 20,000 sq ft of contiguous laboratory space in a new research building (in addition to an adjacent administration area that has 22 offices for faculty and staff).
Moreover, an additional 20,000 sq ft of space is allocated to the LHI and houses a state of art LHI Cardiovascular Clinical Trials Center.
In recent years, the Cardiovascular Division has doubled in size with strategic recruitments in the fields of cardiogenesis, cardiovascular imaging, resuscitation biology, structural heart disease, stem cell biology, myocardial regeneration and molecular genomics.
In addition to this research infrastructure, we have expanded our clinical program through a strategic merger that provides our patients with innovative therapies for heart disease and further extends the opportunities for innovative fellowship clinical care and research opportunities throughout the Twin Cities and Five State area.
Our cardiovascular centers of excellence provide outstanding subspecialty care for our patients in the areas of advanced heart failure, structural and interventional cardiology, imaging, congenital heart disease, electrophysiology, pulmonary hypertension, prevention, cardiac intensive care and cardiac transplantation.
We are committed to excellence in our clinical practice, our research enterprise, and our educational programs.
Page updated
Report abuse